Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
27 studies found for:    Open Studies | "beta-Thalassemia"
Show Display Options
Rank Status Study
21 Recruiting CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Conditions: Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis;   Sickle Cell Disease;   Beta Thalassemia;   Inborn Errors of Metabolism
Interventions: Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
22 Recruiting Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
Conditions: Sickle Cell Disease;   Transfusion Dependent Alpha- or Beta- Thalassemia;   Diamond Blackfan Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Glanzmann Thrombasthenia;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Non-Malignant Hematologic Disorders
Interventions: Drug: Reduced Toxicity Ablative Regimen;   Drug: Reduced Intensity Preparative Regimen;   Drug: Myeloablative Preparative Regimen
23 Recruiting BMT Abatacept for Non-Malignant Diseases
Conditions: Hurler Syndrome;   Fanconi Anemia;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Shwachman-Diamond Syndrome;   Diamond-Blackfan Anemia;   Dyskeratosis-congenita;   Chediak-Higashi Syndrome;   Severe Aplastic Anemia;   Thalassemia Major;   Hemophagocytic Lymphohistiocytosis;   Sickle Cell Disease
Intervention: Drug: Abatacept
24 Recruiting The Role of Endothelin-1 in Sickle Cell Disease
Condition: Sickle Cell Anemia
Interventions: Drug: Ambrisentan;   Drug: Placebo
25 Recruiting Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Drug: panobinostat
26 Recruiting CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Conditions: Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);;   Myelodysplastic Syndrome (MDS);;   Juvenile Myelomonocytic Leukemia (JMML);;   Acute Lymphoblastic Leukemia (ALL);;   Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
27 Recruiting Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-27) Next Page   
Study has passed its completion date and status has not been verified in more than two years.